Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

TEMPO 4:4 Trial Investigators

Research output: Contribution to journalArticle

19 Scopus citations

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this